Holen Sie sich die Stockscreener-App
9.09
0.44%
-0.04
Handel nachbörslich:
9.09
Schlusskurs vom Vortag:
$9.13
Offen:
$9.25
24-Stunden-Volumen:
191.50K
Relative Volume:
0.71
Marktkapitalisierung:
$727.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-83.12M
KGV:
-6.0774
EPS:
-1.4957
Netto-Cashflow:
$-114.50M
1W Leistung:
-12.76%
1M Leistung:
-19.20%
6M Leistung:
-12.51%
1J Leistung:
+0.00%
1-Tages-Spanne:
$8.80
$9.285
1-Wochen-Bereich:
$8.80
$10.78
52-Wochen-Spanne:
$8.70
$14.87
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Company Profile
Firmenname
Bridgebio Oncology Therapeutics Inc
Sektor
Branche
Telefon
857 702 0377
Adresse
256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO
Compare BBOT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBOT
Bridgebio Oncology Therapeutics Inc
|
9.09 | 730.30M | 0 | -83.12M | -114.50M | -1.4957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-11 | Eingeleitet | Stifel | Buy |
| 2026-01-09 | Eingeleitet | Raymond James | Outperform |
| 2025-12-05 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-09-17 | Eingeleitet | Leerink Partners | Outperform |
| 2025-09-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-08-15 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Bridgebio Oncology Therapeutics Inc Aktie (BBOT) Neueste Nachrichten
Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
BBOT: Three next-gen RAS therapeutics show promising efficacy and safety, with key data due in 2026 - TradingView
BBOT: Lead G12C inhibitor and pan-KRAS assets show strong efficacy with key data expected in late 2026 - TradingView
BBOT publishes preclinical data on panKRAS inhibitor BBO-11818 By Investing.com - Investing.com Canada
BridgeBio Oncology’s Narrow Bet on KRAS and PI3K Programs Raises Concentration Risk, Limits Strategic Flexibility - TipRanks
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor - Bitget
BBOT Announces Publication in Cancer Discovery Highlighting - GlobeNewswire
Bridgebio Oncology Therapeutics, Inc. Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is Potent and Selective panKRAS Inhibitor - marketscreener.com
Stifel reiterates Buy on BridgeBio Oncology stock, $23 target By Investing.com - Investing.com Nigeria
Stifel reiterates Buy on BridgeBio Oncology stock, $23 target - Investing.com
BBOT reports Q4 2025 results, $425M cash runway into 2028 - National Today
BridgeBio Oncology Therapeutics 10-K: Net loss $134.0M, EPS $(4.30) - TradingView
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress - The Manila Times
Experimental KRAS drugs show responses as BBOT funds trials into 2028 - Stock Titan
BBOT Technical Analysis & Stock Price Forecast - Intellectia AI
HLXB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
BridgeBio Oncology Therapeutics Inc expected to post a loss of 52 cents a shareEarnings Preview - TradingView
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), BridgeBio Pharma (BBIO) and Establishment Labs Holdings (ESTA) - The Globe and Mail
BBOT: Novel RAS-targeted therapies show strong efficacy and safety, with major data readouts expected soon - TradingView
BBOT: Major data from three RAS-focused assets expected in H2, highlighting strong efficacy and safety - TradingView
HLXB SEC FilingsHelix Acqsn II 10-K, 10-Q, 8-K Forms - Stock Titan
BridgeBio Oncology (BBOT) Stock Analysis Report | Financials & Insights - Benzinga Japan
BBOT to Participate in Upcoming Investor Healthcare Conferences - Bitget
Stifel Initiates Coverage of BridgeBio Oncology Therapeutics (BBOT) with Buy Recommendation - Nasdaq
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Stifel Nicolaus Initiates Coverage on BridgeBio Oncology Therapeutics With Buy Rating, $23 Price Target - marketscreener.com
Stifel initiates coverage on BridgeBio Oncology stock with Buy rating - Investing.com
Stifel initiates coverage on BridgeBio Oncology stock with Buy rating By Investing.com - Investing.com India
Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO), Bristol-Myers Squibb (BMY) and Qiagen (QGEN) - The Globe and Mail
Finance Watch: SPACs Attempt A Comeback As IPO Market Shows Signs Of Life - Citeline News & Insights
Biotech investor Cormorant secures $150M for another SPAC deal - BioPharma Dive
A Look At BridgeBio Oncology Therapeutics (BBOT) Valuation After Recent Share Price Momentum - Yahoo Finance
Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results - Finviz
BridgeBio Oncology Therapeutics (BBOT) Stock Price, News & Analysis - MarketBeat
Top BridgeBio Oncology Therapeutics (BBOT) Competitors 2026 - MarketBeat
BridgeBio Oncology Therapeutics (BBOT) Stock Trends and Sentiment 2026 - MarketBeat
BBOT: Robust efficacy and safety data position these assets as leaders in KRAS-targeted cancer therapy - TradingView — Track All Markets
Raymond James Initiates Coverage of BridgeBio Oncology Therapeutics (BBOT) with Outperform Recommendation - Nasdaq
BridgeBio Oncology stock initiated with Outperform rating at Raymond James By Investing.com - Investing.com Nigeria
Raymond James Initiates BridgeBio Oncology Therapeutics at Outperform With $24 Price Target - marketscreener.com
BridgeBio Oncology stock initiated with Outperform rating at Raymond James - Investing.com
BridgeBio Oncology stock price target raised to $32 from $25 at Leerink - Investing.com Canada
BridgeBio Oncology stock maintains Overweight rating at Morgan Stanley By Investing.com - Investing.com Nigeria
Oppenheimer reiterates Outperform rating on BridgeBio Oncology stock By Investing.com - Investing.com Canada
BridgeBio Oncology stock maintains Overweight rating at Morgan Stanley - Investing.com
BBOT: Promising efficacy and safety for three RAS-pathway inhibitors, with key data expected in 2026 - TradingView — Track All Markets
BridgeBio Oncology reports positive data from RAS-pathway cancer trials - Investing.com
BridgeBio Oncology reports positive data from RAS-pathway cancer trials By Investing.com - Investing.com Nigeria
BridgeBio Oncology Therapeutics, Inc. Announces New Clinical Data for RAS and PI3Kα Programs - TradingView — Track All Markets
Finanzdaten der Bridgebio Oncology Therapeutics Inc-Aktie (BBOT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):